Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lingual Nerve Disruption and Neoadjuvant Chemoimmunotherapy in Tongue Cancer
NCT07346807Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2026
- Primary completion
- Oct 2026
- Modality
- Polymer-based Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, Cisplatin micelle injection (HA132), nab-paclitaxel in tongue squamous cell carcinoma, sponsored by Zhongshan Hospital, Fudan University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tislelizumabCisplatin micelle injection (HA132)nab-paclitaxel
03
Conditions
tongue squamous cell carcinoma
Beyond the preview
Go deeper on NCT07346807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07346807.